Bionano Genomics, Inc.
BNGO
$4.08
-$0.02-0.49%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.07M | 7.77M | 8.77M | 10.72M | 9.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.07M | 7.77M | 8.77M | 10.72M | 9.32M |
| Cost of Revenue | 14.52M | 5.19M | 5.95M | 8.28M | 6.57M |
| Gross Profit | -8.45M | 2.59M | 2.82M | 2.44M | 2.75M |
| SG&A Expenses | 9.46M | 11.56M | 19.73M | 19.68M | 24.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.70M | 23.57M | 35.45M | 39.66M | 45.25M |
| Operating Income | -22.63M | -15.80M | -26.68M | -28.94M | -35.93M |
| Income Before Tax | -44.22M | -16.20M | -31.44M | -43.93M | -112.53M |
| Income Tax Expenses | 24.00K | 26.00K | -18.00K | -36.00K | 39.00K |
| Earnings from Continuing Operations | -44.25M | -16.22M | -31.42M | -43.89M | -112.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.25M | -16.22M | -31.42M | -43.89M | -112.57M |
| EBIT | -22.63M | -15.80M | -26.68M | -28.94M | -35.93M |
| EBITDA | -16.95M | -12.76M | -23.63M | -25.50M | -32.26M |
| EPS Basic | -30.92 | -14.40 | -35.75 | -66.06 | -192.96 |
| Normalized Basic EPS | -10.02 | -10.51 | -19.20 | -45.08 | -37.76 |
| EPS Diluted | -30.92 | -14.40 | -36.00 | -66.17 | -192.96 |
| Normalized Diluted EPS | -10.02 | -10.51 | -19.20 | -45.08 | -37.76 |
| Average Basic Shares Outstanding | 1.43M | 1.13M | 879.00K | 664.40K | 583.40K |
| Average Diluted Shares Outstanding | 1.43M | 1.13M | 879.00K | 664.40K | 583.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
